The evaluation of valsartan biopharmaceutics properties.

Simple item page
dc.contributor.authorCastro, Lara Maria Lopes de
dc.contributor.authorSouza, Jacqueline de
dc.contributor.authorCaldeira, Tamires Guedes
dc.contributor.authorMapa, Bruna de Carvalho
dc.contributor.authorSoares, Anna Flávia Matos
dc.contributor.authorGomes, Bruna Pegorelli
dc.contributor.authorCroce, Carolina Carvalho Della
dc.contributor.authorBarcellos, Neila Marcia Silva
dc.date.accessioned2020-05-22T16:18:57Z
dc.date.available2020-05-22T16:18:57Z
dc.date.issued2020
dc.description.abstractBackground: Solubility, intestinal permeability and dissolution are the main factors that govern the rate and extent of drugs absorption and are directly related to bioavailability. Biopharmaceutics Classification System (BCS) is an important tool that uses in vitro results for comparison with bioavailability in vivo (biowaiver). Valsartan is widely used in the treatment of hypertension and shows different BCS classification in the literature (BCS class II or III). Objective: This work proposes the study of valsartan biopharmaceutics properties and its BCS classification. Method: High performance liquid chromatography (HPLC) method was developed and validated to quantify the drug in buffers pH 1.2, 4.5 and 6.8. Valsartan solubility was determined in these three different media using shake flask method and intrinsic dissolution rate. Evaluation of dissolution profile from coated tablets was conducted. Results: The low solubility (pH 1.2 and 4.5) and high solubility (pH 6.8) was observed for both solubility methods. Permeability data reported from literature showed that valsartan is a low permeability drug. Valsartan presented rapid release profile only in pH 6.8. Conclusion: We defined that valsartan is a class IV drug, in disagreement with what has been published so far. It is important to emphasize that the conditions considered here are the indicated to define the biopharmaceutics classification by regulatory agencies.pt_BR
dc.identifier.citationCASTRO, L. M. L. et al. The evaluation of valsartan biopharmaceutics properties. Current Drug Research Reviews, v. 12, p. 1-11, 2020. Disponível em: <http://www.eurekaselect.com/177319/article>. Acesso em: 10 fev. 2020.pt_BR
dc.identifier.doihttps://doi.org/10.2174/2589977511666191210151120pt_BR
dc.identifier.issn2589-9783
dc.identifier.urihttp://www.repositorio.ufop.br/handle/123456789/12242
dc.identifier.uri2http://www.eurekaselect.com/177319/articlept_BR
dc.language.isoen_USpt_BR
dc.rightsrestritopt_BR
dc.subjectBiopharmaceutics classification systempt_BR
dc.subjectSolubilitypt_BR
dc.subjectPermeabilitypt_BR
dc.subjectDissolutionpt_BR
dc.subjectBiowaiverpt_BR
dc.titleThe evaluation of valsartan biopharmaceutics properties.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ARTIGO_EvaluationValsartanBiopharmaceutics.pdf
Size:
529.82 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
924 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
DEFAR - Artigos publicados em periódicos